Background illustration for clinical trials search

Small Cell Lung Cancer Clinical Trials

Browse 642 small cell lung cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

for
Non-Small Cell Lung Cancer
Location: Burlington MA, Hartford CT, New Haven CT, Lebanon NH,
Sponsor: Summit Therapeutics

Sex: All

Age: 18+

Code: NCT05899608

Phase3, Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

for
Non-small Cell Lung Cancer
Location: Sydney, Saint John, Scarborough ME, West Haven CT,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT06692738

Phase3, Recruiting

BostonGene and Exigent Genomic INsight Study

for
Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Sarcoma
Location: Fort Wayne IN, Rogers AR, Houston TX, Tulsa OK,
Sponsor: BostonGene

Sex: All

Age: 18+

Code: NCT06272864

Recruiting

KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC

for
Non-Small Cell Lung Cancer
Location: Baltimore MD
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Sex: All

Age: 18 - 70+

Code: NCT05254184

Phase1, Recruiting

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

for
Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype,
Location: Boston MA, Boynton Beach FL, Nashville TN, Dallas TX,
Sponsor: Neonc Technologies, Inc.

Sex: All

Age: 18+

Code: NCT06047379

Phase1, Phase2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

for
Non-Small Cell Lung Cancer, NSCLC,
Location: Boston MA, New Haven CT, New York NY, Tampa FL,
Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Sex: All

Age: 18+

Code: NCT06917079

Phase1, Recruiting

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

for
Non-Small Cell Lung Cancer, NSCLC,
Location: Boston MA, Westbury NY, New York NY, Washington D.C. DC,
Sponsor: Revolution Medicines, Inc.

Sex: All

Age: 18+

Code: NCT06162221

Phase1, Phase2, Recruiting

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

for
Non Small Cell Lung Cancer, Triple Negative Breast Cancer,
Location: Boston MA, Buffalo NY, Orlando FL, Sarasota FL,
Sponsor: Compass Therapeutics

Sex: All

Age: 18+

Code: NCT06150664

Phase1, Recruiting

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

for
Non-small Cell Lung Cancer,
Location: New Haven CT, Norwalk CT, New York NY, Montreal,
Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Sex: All

Age: 18+

Code: NCT06343402

Phase1, Recruiting

Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

for
Non Small Cell Lung Cancer, NSCLC, Stage III, Nsclc
Location: Stanford CA
Sponsor: Maximilian Diehn

Sex: All

Age: 18+

Code: NCT04585490

Phase3, Recruiting

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

for
Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer,
Location: Sherbrooke, Chicoutimi, Nyack NY, Albany NY,
Sponsor: Pfizer

Sex: All

Age: 18+

Code: NCT07222566

Phase3, Recruiting

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

for
Non-small Cell Lung Cancer (NSCLC)
Location: The Bronx NY, Albany NY, East Brunswick NJ,
Sponsor: Genmab

Sex: All

Age: 18+

Code: NCT07288177

Phase2, Recruiting

Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers

for
Non-small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer,
Location: Columbia MO
Sponsor: University of Missouri-Columbia

Sex: All

Age: 18+

Code: NCT02838836

Recruiting

Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

for
Non-small Cell Lung Cancer (NSCLC)
Location: Pittsburgh PA
Sponsor: Olivera Finn

Sex: All

Age: 18+

Code: NCT01720836

Phase1, Phase2, Recruiting

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

for
Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma,
Location: Boston MA, New Haven CT, Buffalo NY, Tampa FL,
Sponsor: Simcha IL-18, Inc.

Sex: All

Age: 18+

Code: NCT04787042

Phase1, Phase2, Recruiting

Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

for
Non Small Cell Lung Cancer, NSCLC, KRAS G12C
Location: Richmond VA, Charlottesville VA, Columbus OH
Sponsor: Ryan Gentzler, MD

Sex: All

Age: 18+

Code: NCT06248606

Phase2, Recruiting

A Study of KK2269 in Adult Participants With Solid Tumors

for
Advanced Solid Tumor, Metastatic Solid Tumor,
Location: Jacksonville FL, St Louis MO, Dallas TX, Scottsdale AZ,
Sponsor: Kyowa Kirin Co., Ltd.

Sex: All

Age: 18+

Code: NCT06266299

Phase1, Recruiting

Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

for
Extensive Stage Small Cell Lung Cancer
Location: Ann Arbor MI, Chicago IL, Houston TX, Sioux Falls SD,
Sponsor: Amgen

Sex: All

Age: 18+

Code: NCT06598306

Phase1, Recruiting

BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors

for
Solid Tumors, Non Small Cell Lung Cancer,
Location: New Haven CT
Sponsor: BioInvent International AB

Sex: All

Age: 18+

Code: NCT06205706

Phase1, Phase2, Recruiting

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

for
Advanced Non-Small Cell Lung Cancer, Squamous Cell Carcinoma,
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 70+

Code: NCT02133196

Phase2, Recruiting